



Neurochem

275, boul. Armand-Frappier
Laval (Québec) Canada
H7V 4A7

Tél. : (450) 680-4500
Fax : (450) 680-4501
Web : www.neurochem.com

Dr. Eric Abadie
CHMP Chair
European Medicines Agency (EMA)
7 Westferry Circus
Canary Wharf
London, E14 4HB,
United Kingdom

13 March 2008

Subject: Withdrawal of KIIACTA (eprodilate disodium) capsules, 400 mg MAA
Neurochem Luxco II SARL EMA/H/C/000779

Dear Dr. Abadie,

Please be informed that we wish to withdraw the application for Marketing Authorisation of KIIACTA (eprodilate disodium) capsules, 400 mg, which was intended to be used for the treatment of amyloid A amyloidosis (EMA/H/C/000779).

This withdrawal is based on the request by the CHMP for an additional placebo controlled study, which we are not able to provide within the timeframe allowed by the Centralised Procedure.

We reserve the right to make further submissions at a future date for this or other therapeutic indications. We plan to seek Scientific Advice/Protocol Assistance in the near future regarding the design of the additional study.

We have no objection to publication of this withdrawal notice on the EMA website.

Yours sincerely,

Neurochem Inc.